#1EXACT SCIENCES Cowen Liquid Biopsy Summit Kevin Conroy, Chairman and CEO September 24, 2020 XXXXXX XX X XX XX D x#2Safe harbor statement Forward-Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission. Specifically, the Company's annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections of forward-looking statements. EXACT SCIENCES 2#3Leading, global, advanced cancer diagnostics company EXACT SCIENCES United States Brazil Headquarters Russia China Offices *Includes Genomic Health revenue prior to November acquisition close Australia 4,000+ employees 1,000+ commercial organization 250+ skilled R&D employees $1.3B Proforma 2019 revenue* 3#4Steps to successfully bring new cancer screening tests to patients and physicians Marker discovery EXACT SCIENCES Sample collection Platform technology Clinical trials Regulatory expertise Insurance coverage Lab infrastructure IT foundation Customer service Sales & marketing strength 4#5Marker discovery Marker discovery MAYO CLINIC T Systematically identifying markers with Mayo Clinic EXACT SCIENCES Sample collection. Platform technology 97% Average accuracy of methylation markers identified across top cancers in tissue* Clinical trials Regulatory expertise Insurance coverage Lab infrastructure *As defined by AUC (area under the curve), a measure of both sensitivity and specificity ~3,000 Patents filed for discovered markers IT foundation Customer service Sales & marketing strength 5#6EXACT SCIENCES DIXX XIX DUX XXX DEXXX XIX XXX XIX XUX DUX XIX DUX XIX DUX DUXX DUX DIXX DIX XUX DUXX DUXX XUX DU XIX XIX DUX XIX XUX DUX XIX XIX XUX XXX DUX XXX XUX XIX DUX XIX DUX XXX XUX XUXX 1X XUX XUX DUX DUX DUX XIX XUX XXX XIX XIX DUX DUX XUX DUX DUX XIX XUX DUX DUX XIX DUX DUX DIXX DIX DUX DUX ↓ DIX DUX DIX XIX DUX XIX DUX XUX DIX ↓ XXX XIX IX XIX XIX DUX XIX XIX DUX XUX DUX XUX XIX XUXX XUX DUX Discover markers in tissue Validate in blood [TUT] accurate in both Identify markers >95% Marker discovery process#7Sample collection. Marker discovery EXACT SCIENCES 215,000+ Banked blood samples Sample collection. Platform technology Clinical trials Regulatory expertise Insurance coverage Superior blood preservation. with LBGard tube* Lab infrastructure *Tube and technology acquired in Biomatrica acquisition IT foundation Customer service Sales & marketing strength 7#8Platform technology Marker discovery EXACT SCIENCES Sample collection. Sophisticated platform well-suited to blood testing Platform technology Clinical trials Regulatory expertise Differentiated DNA extraction, PCR, & sequencing capabilities Insurance coverage Lab infrastructure IT foundation Customer service Sales & marketing strength 8#9Clinical trials Marker discovery EXACT SCIENCES Sample collection. 10,000+ Person trials: DeeP-C, BLUE-C, TAILORX, TIDAL, Voyage Platform technology Clinical trials Regulatory expertise Insurance coverage 600+ Abstracts and publications* Lab infrastructure *Includes Genomic Health publications prior to acquisition IT foundation Customer service Sales & marketing strength 9#10Regulatory expertise Marker discovery EXACT SCIENCES S FDA PALMETTO GBA MolDXⓇ Sample collection. Platform technology CMS CENTERS FOR MEDICARE & MEDICAID SERVICES (NCQA Clinical trials Regulatory expertise AMERICAN CANCER SOCIETYⓇ Insurance coverage U.S. Preventive Services TASK FORCE Lab infrastructure National Comprehensive NCCN Cancer Network® IT foundation Customer service Sales & marketing strength 10